XFOR logo

XFOR
X4 Pharmaceuticals Inc

3,490
Mkt Cap
$371.62M
Volume
263,889.00
52W High
$4.83
52W Low
$1.35
PE Ratio
-0.87
XFOR Fundamentals
Price
$3.94
Prev Close
$4.00
Open
$3.97
50D MA
$4.15
Beta
1.51
Avg. Volume
397,424.19
EPS (Annual)
-$1.87
P/B
2.21
Rev/Employee
$780,288.89
$7.34
Loading...
Loading...
News
all
press releases
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now...
Yahoo! Finance: News·2d ago
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative...
MarketBeat·10d ago
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +11.86% and -67.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
X4 Pharmaceuticals (XFOR) to Release Earnings on Thursday
X4 Pharmaceuticals (NASDAQ:XFOR) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Trading Up 0.7% - Time to Buy?
X4 Pharmaceuticals (NASDAQ:XFOR) Trading 0.7% Higher - Here's Why...
MarketBeat·1mo ago
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Q3 Earnings Forecast for XFOR Issued By Brookline Cap M
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Cap M issued their Q3 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann anticipates that the company will...
MarketBeat·2mo ago
News Placeholder
Research Analysts Set Expectations for XFOR Q1 Earnings
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann forecasts that the company will post earning...
MarketBeat·2mo ago
<
1
2
...
>

Latest XFOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.